30 APRIL 2025

EQUITY RESEARCH - COMPANY REPORT

MEGA LIFESCIENCES

THAILAND / COMMERCE

MEGA TB

ยังคงเผชิญอุปสรรคจากเมียนมาร์

- การเพิ่มขึ้นของรายได้จาก Branded ไม่น่าจะชดเชยการลดลงของรายได้จาก ธุรกิจในเมียนมาร์ได้ เราคาดกำไรปกติ 1Q25 -23.8% q-q, -1.1% y-y.
- คงประมาณการกำไร
- ปรับลดราคาเป้าหมายเป็น 36 บาทจากความเสี่ยงเพิ่ม คงคำแนะนำซื้อ

สถานการณ์ในเมียนมาร์ยังคงฉุดรั้งแนวโน้มการเติบโตของ MEGA

เราคาดว่า MEGA จะเริ่มไตรมาสแรกของปีด้วยกำไรที่ไม่แข็งแกร่งนัก ลดลง y-y เล็กน้อย แต่ลดลงค่อนข้างมาก q-q ตามฤดูกาล ด้วยเหตุผลเดียวกับช่วง 2 ปีที่ผ่านมา คือธุรกิจ Distribution ในเมียนมาร์ถดถอยลงอย่างต่อเนื่องและยังไม่มีแนวโน้มจะดีขึ้น แม้จะมีผลต่อกำไรจำกัด เนื่องจากปัจจุบันธุรกิจ Distribution ซึ่งมีมาร์จิ้นต่ำ มีสัดส่วน ต่อรายได้รวม 25% ลดลงจาก 30% ในช่วง 3 ปีก่อนหน้า อย่างไรก็ตาม บริษัทยัง จำเป็นต้องควบคุมต้นทุนและค่าใช้จ่ายอย่างเข้มข้น เพื่อชดเชยการถดถอยอย่างรวดเร็ว ของธุรกิจในเมียนมาร์ MEGA จึงไม่สามารถเติบโตได้เต็มที่อย่างที่ควรจะเป็นเพราะมี ธุรกิจในเมียนมาณร์ฉุดรั้ง

มาร์จิ้นเพิ่มขึ้นจาก Product mix

เราคาดกำไรสุทธิ รวม FX loss 100 ล้านบาทใน 1Q25 ที่ 469 ล้านบาท (-26.7% q-q, -1.8% y-y) ส่วนกำไรปกติ คาด 469 ล้านบาท (-23.8% q-q, -1.1% y-y) บนสมมติฐาน รายได้จากการขายรวม -6.9% q-q, -8.8% y-y เหลือ 3.4 พันล้านบาท การเติบโตของ รายได้จาก Branded business ไม่น่าจะมากพอที่จะชดเชยรายได้จาก Distribution ที่มี แนวโน้มลดลงเกือบ 30% y-y ได้ แต่อัตรากำไรขั้นต้นมีทิศทางดีขึ้น y-y เราคาดที่ 51.2% จากสัดส่วนของ Branded business ที่เพิ่มขึ้น ทั้งนี้ ในช่วง 2 ปีที่ผ่านมา บริษัท รักษาอัตรากำไรขั้นต้นของ Branded ได้อย่างมีสเถียรภาพในกรอบ 65%-66%% การ เพิ่มขึ้นของอัตรากำไรขั้นต้นโดยรวม มาจากสัดส่วนชอง Distribution ที่ลดลง มากกว่า จะมาจากการขยายอัตรากำไรของ Branded business

กำไรที่คาดคิดเป็น 22% ของทั้งปี คงประมาณการ

กำไรปกติ 1Q25 ที่เราคาด คิดเป็น 22% ของประมาณทั้งปีที่ 2.2 พันล้านบาท (-0.7% y-y) ในขณะที่แนวโน้มในไตรมาสที่เหลือของปี ไม่น่าแตกต่างจาก 1Q25 ยกเว้น เปลี่ยนแปลงตามฤดูกาล (4Q ดีที่สุด) เราจึงยังคงประมาณการไว้ก่อน

ลดราคาเป้าหมายจากความเสี่ยงเพิ่ม คงคำแหะหำซื้อจาก Valuations ถูก


แม้ว่ากำลังซื้อในเมียนมาร์จะถดถอย แต่ธุรกิจยาในนั้นยังแข็งแกร่ง อย่างไรก็ตาม เรา ปรับลดราคาเป้าหมายลงเป็น 36 บาท โดยปรับเพิ่ม WACC เป็น 9.4% จาก 8.9% ตาม beta ที่สูงขึ้น ราคาเป้าหมายใหม่คิดเป็น 2025E Implied P/E 14x หรือ -0.5SD ของ ค่าเฉลี่ย 5 ปี เชื่อว่าน่าจะ conservative เพียงพอ คำแนะนำยังเป็นซื้อ จาก Valuations ถูกและคาด Dividend yield 5% UNCHANGED TARGET PRICE THB36.00 CLOSE THB29.50 UP/DOWNSIDE +22.0% PRIOR TP THB40.00 CHANGE IN TP -10.0%

+5.8%

KEY STOCK DATA

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	15,344	14,845	15,560	16,254
Net profit	2,013	2,220	2,397	2,686
EPS (THB)	2.31	2.55	2.75	3.08
vs Consensus (%)	-	(6.0)	(5.1)	5.4
EBITDA	3,756	2,983	3,201	3,517
Recurring net profit	2,237	2,220	2,397	2,686
Core EPS (THB)	2.57	2.55	2.75	3.08
Chg. In EPS est. (%)	-	-	-	-
EPS growth (%)	(3.9)	(0.7)	8.0	12.1
Core P/E (x)	8.3	11.6	10.7	9.6
Dividend yield (%)	5.4	5.4	5.6	5.8
EV/EBITDA (x)	6.0	7.4	7.0	6.4
Price/book (x)	2.6	2.6	2.6	2.5
Net debt/Equity (%)	(33.6)	(36.2)	(33.8)	(32.2)
ROE (%)	32.3	22.5	24.2	26.4

TP vs CONSENSUS



Sources: Bloomberg consensus; FSSIA estimates



Jitra Amornthum Fundamental Investment Analyst on Securities; License no. 014530 jitra.a@fssia.com, +66 2646 9966

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT



Investment thesis

Excluding an expected FX loss of THB100m, we forecast a core profit of THB489m (-23.8% q-q, -1.1% y-y) in 1Q25. This is based on an expected sales revenue decline of 6.9% q-q and 8.8% y-y to THB3.4b. Revenue growth from the branded business is unlikely to offset the decline in distribution revenue. The estimated core profit for 1Q25 accounts for 22% of our full-year forecast. We expect earnings trends in the remaining quarters to be broadly similar to 1Q25, aside from seasonal variations.

We cut our TP to THB36, reflecting a higher WACC of 9.4% (up from 8.9%) due to an increased beta. We maintain our BUY rating on the cheap valuations and an expected dividend yield of 5%.

Company profile

MEGA is a leading manufacturer and distributor of pharmaceutical, nutraceutical products and fast-moving consumer goods (FMCG) in developing countries such as Myanmar, Vietnam and Cambodia. MEGA also develops, manufactures, and sells its nutraceutical products, generic prescription pharmaceutical products, and OTC products under the Mega We Care brand through its distribution network and third-party distributors in 36 countries across the world.

www.megawecare.com

Catalysts

Key potential catalysts include 1) expedited medicine registrations and listings; 2) widespread medical events such as the Covid-19 pandemic; and 3) the success of new products and markets.

Risks to our call

Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Event calendar

 Date
 Event

 14 May 2025
 1Q25 earnings announcement

Principal activities (revenue, 2024)

- Mega We Care 54.6 %
- Maxxcare 43.5 %
 OEM 2.0 %
 Source: Mega Lifesciences

Major shareholders

- Unistretch Co Ltd 49.8 %
- Thai NVDR 8.0 %
- Mr. Vivek Dhawan 5.3 %
- Others 36.9 %



Source: Mega Lifesciences

Key assumptions

	(unit)	2025E	2026E	2027E
Branded business	(THB m)	8,864	9,573	10,147
Growth	(%)	6.0	8.0	6.0
Gross margin	(%)	65.0	64.8	65.0
Distribution business	(THB m)	5,667	5,667	5,781
Growth	(%)	(15.0)	0.0	2.0
Gross margin	(%)	23.0	22.8	22.5
SG&A to sales (%)	(%)	30.5	30.5	29.8

Source: FSSIA estimates

Earnings sensitivity

- For every 5% change in branded revenue, we project MEGA's 2025 net profit to change by 6%, all else being equal.
- For every 5% change in distribution revenue, we project MEGA's 2025 net profit to change by 1%, all else being equal.
- For every 1% change in overall gross margin, we project MEGA's 2025 net profit to change by 6%, all else being equal.

Source: FSSIA estimates




Exhibit 1: MEGA – 1Q25 earnings preview

Year to Dec 31	1Q24	2Q24	3Q24	4Q24	1Q25E	Cha	nge	2024	2025E	Change	% of
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)	2025E				
Sales	3,733	3,954	4,001	3,657	3,405	(6.9)	(8.8)	15,344	14,845	(3.3)	22.9
Cost of sales	(1,984)	(2,038)	(1,866)	(1,702)	(1,662)	(2.3)	(16.2)	(7,590)	(7,686)	1.3	21.6
Gross profit	1,749	1,916	2,135	1,955	1,743	(10.8)	(0.3)	5,469	5,393	(1.4)	32.3
Operating costs	(1,066)	(1,140)	(1,099)	(1,079)	(1,065)	(1.3)	(0.1)	(4,385)	(4,528)	3.3	23.5
Operating profit	682	776	1,035	876	678	(22.6)	(0.6)	3,473	2,683	(22.7)	25.3
Operating EBITDA	775	872	1,138	971	771	(20.6)	(0.5)	3,756	2,983	(20.6)	25.9
Other income	22	26	32	23	21	(7.6)	(4.1)	103	52	(49.5)	40.4
Interest expense	(5)	(9)	(10)	(14)	(12)	(12.1)	134.4	(38)	(41)	6.0	29.4
FX gain/loss	(151)	(187)	(601)	(143)	(110)	nm	nm	(1,082)	0	nm	nm
Profit before tax	699	793	1,057	885	687	(22.4)	(1.7)	3,434	2,643	(23.1)	26.0
Tax	(71)	(93)	(73)	(103)	(109)	5.6	53.3	(340)	(423)	24.5	25.7
Reported net profit	478	513	383	640	469	(26.7)	(1.8)	2,013	2,220	10.3	21.1
Core profit	494	557	544	642	489	(23.8)	(1.1)	2,237	2,220	(0.7)	22.0
Reported EPS (THB)	0.55	0.59	0.44	0.73	0.54	(26.7)	(1.8)	2.31	2.55	10.3	21.1
Core EPS (THB)	0.57	0.64	0.62	0.74	0.56	(23.8)	(1.1)	2.57	2.55	(0.7)	22.0
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	
Gross margin	46.8	48.5	53.4	53.5	51.2	(2.3)	4.3	50.5	48.2	(2.3)	
Operating margin	18.9	20.3	26.7	24.6	20.5	(4.0)	1.7	22.6	18.1	(4.6)	
EBITDA margin	20.8	22.1	28.5	26.5	23.1	(3.4)	2.3	24.5	20.1	(4.4)	
Net margin	12.8	13.0	9.6	17.5	13.8	(3.7)	1.0	13.1	15.0	1.8	
SG&A / Sales	28.6	28.8	27.5	29.5	31.3	1.8	2.7	28.6	30.5	1.9	
Revenue breakdown	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)					
Branded business	1,930	2,140	2,033	2,268	2,104	(7.2)	9.0	8,371	8,864	5.9	
Distribution business	1,737	1,746	1,865	1,320	1,235	(6.4)	(28.9)	6,667	5,667	(15.0)	
OEM business	65	68	104	69	66	(4.8)	1.7	306	314	2.5	
Gross margin by business unit	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)	
Branded business	64.3	66.0	65.2	65.7	66.0	0.5	2.6	65.9	65.0	(0.9)	
Distribution business	27.9	27.8	38.4	33.6	27.0	(19.6)	(3.2)	31.9	23.0	(8.9)	
OEM business	34.9	26.1	41.3	31.5	32.0	1.6	(8.3)	34.7	30.0	(4.7)	


Sources: MEGA, FSSIA estimates

Exhibit 2: Revenue structure and blended gross margin




Sources: MEGA, FSSIA estimates

Exhibit 3: Branded business and gross margin



Sources: MEGA, FSSIA estimates






Sources: MEGA, FSSIA estimates

Exhibit 6: One-year rolling forward P/E band



Sources: Bloomberg, FSSIA estimates

Exhibit 5: Net profit and net margin



Sources: MEGA, FSSIA estimates





Sources: Bloomberg, FSSIA estimates

Financial Statements

Mega Lifesciences

Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Revenue	15,681	15,344	14,845	15,560	16,254
Cost of goods sold	(8,586)	(7,590)	(7,686)	(7,969)	(8,260)
Gross profit	7,095	7,754	7,159	7,591	7,994
Other operating income	95	103	52	47	49
Operating costs	(4,191)	(4,385)	(4,528)	(4,746)	(4,844)
Operating EBITDA	3,285	3,756	2,983	3,201	3,517
Depreciation	(286)	(283)	(300)	(309)	(318)
Goodwill amortisation	0	0	0	0	0
Operating EBIT	2,999	3,473	2,683	2,892	3,199
Net financing costs	(31)	(38)	(41)	(40)	(40)
Associates	0	0	0	0	0
Recurring non-operating income	0	0	0	0	0
Non-recurring items	(707)	(1,082)	0	0	0
Profit before tax	2,262	2,352	2,643	2,853	3,160
Тах	(269)	(340)	(423)	(456)	(474)
Profit after tax	1,993	2,013	2,220	2,397	2,686
Minority interests	-	-	-	-	-
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	1,993	2,013	2,220	2,397	2,686
Non-recurring items & goodwill (net)	335	234	0	0	0
Recurring net profit	2,327	2,237	2,220	2,397	2,686
Per share (THB)					
Recurring EPS *	2.67	3.557	2.55	2.75	3.08
Reported EPS	2.29	2.31	2.55	2.75	3.08
DPS	1.60	1.60	1.60	1.65	1.73
Diluted shares (used to calculate per share data)	872	872	872	872	872
Growth					
Revenue (%)	0.0	(2.1)	(3.3)	4.8	4.5
Operating EBITDA (%)	8.3	14.3	(20.6)	7.3	9.9
Operating EBIT (%)	8.6	15.8	(22.7)	7.8	10.6
Recurring EPS (%)	1.6	(3.9)	(28.3)	8.0	12.1
Reported EPS (%)	(11.1)	1.0	10.3	8.0	12.1
Operating performance					
Gross margin inc. depreciation (%)	45.2	50.5	48.2	48.8	49.2
Gross margin exc. depreciation (%)	47.1	52.4	50.2	50.8	51.1
Operating EBITDA margin (%)	21.0	24.5	20.1	20.6	21.6
Operating EBIT margin (%)	19.1	22.6	18.1	18.6	19.7
Net margin (%)	17.2	20.2	15.0	15.4	16.5
Effective tax rate (%)	11.9	14.4	16.0	16.0	15.0
Dividend payout on recurring profit (%)	51.7	45.1	63.0	60.0	56.0
Interest cover (X)	96.0	90.2	65.7	73.2	81.0
Inventory days	164.6	160.1	149.3	145.6	144.0
Debtor days	80.9	81.3	79.1	74.7	72.9
Creditor days	157.6	140.2	129.9	134.3	126.6
Operating ROIC (%)	58.0	64.3	48.1	51.7	53.8
ROIC (%)	39.8	45.0	33.8	36.4	38.7
ROE (%)	29.9	32.3	22.5	24.2	26.4
ROA (%)	19.0	22.1	15.7	16.6	18.4
* Pre-exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2023	2024	2025E	2026E	2027E
Mega We Care	8,005	8,371	8,864	9,573	10,147
Maxxcare	7,397	6,667	5,667	5,667	5,781
OEM	280	306	314	320	326

Sources: Mega Lifesciences; FSSIA estimates

Financial Statements

Mega Lifesciences

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
ecurring net profit	2,699	3,095	2,220	2,397	2,686
epreciation	286	283	300	309	318
ssociates & minorities	0	0	0	0	C
ther non-cash items	671	(357)	(330)	(370)	(369)
hange in working capital	(1,023)	(509)	42	(585)	(844)
ash flow from operations	2,633	2,512	2,232	1,750	1,792
apex - maintenance	-	-	-	-	
apex - new investment	(294)	(230)	(578)	(440)	(390)
et acquisitions & disposals	-	-	-	-	(
other investments (net)	44	231	(2)	0	C
ash flow from investing	(250)	1	(579)	(440)	(390)
ividends paid	(1,439)	(1,395)	(1,399)	(1,438)	(1,504)
quity finance	0	0	0	0	(1,004)
lebt finance	(237)	155	1	3	(3)
other financing cash flows	(32)	(38)	(41)	(40)	(40)
Cash flow from financing			. ,	. ,	
-	(1,708)	(1,277)	(1,438)	(1,474)	(1,547)
lon-recurring cash flows	-	-	-	-	
other adjustments	0	0	31	0	110
let other adjustments	(751)	(135)	31	(31)	110
lovement in cash	(76)	1,101	245	(195)	(35)
ree cash flow to firm (FCFF)	2,414.24	2,552.10	1,692.89	1,349.88	1,441.01
ree cash flow to equity (FCFE)	1,362.98	2,495.78	1,643.42	1,242.82	1,468.77
er share (THB)					
CFF per share	2.77	2.93	1.94	1.55	1.65
CFE per share	1.56	2.86	1.88	1.43	1.68
Recurring cash flow per share	4.19	3.46	2.51	2.68	3.02
alance Sheet (THP m) Year Ending Dee	2022	2024	2025E	20265	- 20275
Balance Sheet (THB m) Year Ending Dec	2023			2026E	2027E
angible fixed assets (gross)	4,309	4,571	5,149	5,589	5,979
ess: Accumulated depreciation	(2,334)	(2,624)	(2,924)	(3,233)	(3,551)
angible fixed assets (net)	1,974	1,947	2,225	2,356	2,428
ntangible fixed assets (net)	1,318	1,319	1,300	1,356	1,331
ong-term financial assets	0	0	0	0	C
nvest. in associates & subsidiaries	221	40	40	40	40
cash & equivalents	2,712	3,813	4,058	3,863	3,828
/C receivable	3,570	3,264	3,172	3,197	3,295
nventories	3,377	3,033	3,011	3,100	3,168
Other current assets	330	117	166	174	182
Current assets	9,990	10,227	10,408	10,335	10,473
Other assets	611	678	597	597	596
otal assets	14,115	14,210	14,570	14,684	14,869
	9,302	9,877	9,854	9,969	10,351
Common equity		,			
Ainorities etc.	0	0	0	0	(
otal shareholders' equity	9,302	9,877	9,854	9,969	10,351
ong term debt	132	140	139	140	138
Other long-term liabilities	244	279	223	224	224
ong-term liabilities	376	419	361	364	363
/C payable	3,197	2,416	2,843	2,795	2,716
hort term debt	120	351	354	356	354
ther current liabilities	1,119	1,146	1,158	1,201	1,086
urrent liabilities	4,437	3,914	4,354	4,351	4,156
otal liabilities and shareholders' equity	14,115	14,210	14,570	14,684	14,869
let working capital	2,961	2,851	2,349	2,476	2,844
ivested capital	7,086	6,834	6,511	6,826	7,240
Includes convertibles and preferred stock which is bei		-,	-,	-,	.,
er share (THB)					
book value per share	10.67	11.33	11.30	11.43	11.87
angible book value per share	9.16	9.82	9.81	9.88	10.35
inancial strength	0.10	0.02	0.01	0.00	10.00
-	10 ··	(00 -)	(00 =)	(00 -)	/ ··
let debt/equity (%)	(26.4)	(33.6)	(36.2)	(33.8)	(32.2)
let debt/total assets (%)	(17.4)	(23.4)	(24.5)	(22.9)	(22.4
current ratio (x)	2.3	2.6	2.4	2.4	2.5
F interest cover (x)	54.0	71.8	55.4	43.6	48.1
aluation	2023	2024	2025E	2026E	2027E
ecurring P/E (x) *	9.5	8.3	11.6	10.7	9.6
Recurring P/E @ target price (x) *	11.3	9.9	13.7	12.7	11.4
eported P/E (x)	12.9	12.8	11.6	10.7	9.6
ividend yield (%)	5.4	5.4	5.4	5.6	5.8
rice/book (x)	2.8	2.6	2.6	2.6	2.5
rice/tangible book (x)	3.2	3.0	3.0	3.0	2.9
V/EBITDA (x) **	7.1	6.0	7.4	7.0	6.4
V/EBITDA @ target price (x) **	8.5	7.2	9.0	8.5	7.7
V/invested capital (x)	3.3	3.3	3.4	3.3	3.1

Sources: Mega Lifesciences; FSSIA estimates



MEGA LIFESCIENCES PCL (MEGA TB)

FSSIA ESG rating

 $\star \star \star$

54.48 /100

Exhibit 8: FSSIA ESG score implication

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
$\star \star \star \star$	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Source: FSSIA estimates

Exhibit 9: ESG – peer comparison

	FSSIA			Domestie	c ratings			Global ratings						Bloomberg		
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score	
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17	
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94	
COM7	61.78		Y	Y	5.00	5.00	Certified	Low	47.75			52.68	21.00	4.40	43.59	
MEGA	54.48		Y	Y	4.00	4.00	Declared	Medium	66.56			58.59	24.00	2.39		
BJC	71.33	Y	Y	Y	4.00	4.00		Medium	55.09	Α		65.19	89.00	2.16		
CRC	64.49		Y	Y	5.00	5.00	Certified	Medium		BBB		60.98	73.00	2.90	47.27	

Sources: SETTRADE.com; FSSIA's compilation

Exhibit 10: ESG score by Bloomberg

FY ending Dec 31	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	-	2.29	_
BESG environmental pillar score	_	1.86	—
BESG social pillar score	_	1.06	_
BESG governance pillar score	_	4.54	_
ESG disclosure score	44.34	53.36	—
Environmental disclosure score	29.84	44.22	—
Social disclosure score	19.44	32.16	—
Governance disclosure score	83.59	83.59	_
Environmental			
Emissions reduction initiatives	Yes	Yes	Yes
Climate change policy	Yes	Yes	No
Climate change opportunities discussed	No	No	No
Risks of climate change discussed	No	No	No
GHG scope 1	_	—	633
GHG scope 2 location-based	_	_	6
GHG Scope 3	_	_	0
Carbon per unit of production	_	_	—
Biodiversity policy	No	No	No
Energy efficiency policy	Yes	Yes	Yes
Total energy consumption	24	24	23
Renewable energy use	1	1	1
Electricity used	12	13	12
Fuel used - natural gas	—	_	914

Sources: Bloomberg; FSSIA's compilation

Exhibit 11: ESG score by Bloomberg (cont.)

FY ending Dec 31	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No
Waste reduction policy	Yes	Yes	Yes
Hazardous waste	—	—	0
Total waste	1	1	1
Waste recycled	0	0	_
Waste sent to landfills	—	—	_
Environmental supply chain management	Yes	Yes	No
Water policy	No	Yes	Yes
Water consumption	—	_	0
Social			
Human rights policy	Yes	Yes	Yes
Policy against child labor	Yes	Yes	Yes
Quality assurance and recall policy	No	Yes	Yes
Consumer data protection policy	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes
Gender pay gap breakout	No	No	No
Pct women in workforce	56	56	56
Pct disabled in workforce	_	_	_
Business ethics policy	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes
Health and safety policy	Yes	Yes	No
Lost time incident rate - employees	0	0	_
Total recordable incident rate - employees	_	—	_
Training policy	Yes	Yes	Yes
Fair remuneration policy	No	No	No
Number of employees – CSR	5,714	6,021	5,767
Employee turnover pct	_	19	_
Total hours spent by firm - employee training	70,551	79,892	70,826
Social supply chain management	Yes	Yes	Yes
Governance			
Board size	10	10	10
No. of independent directors (ID)	4	4	4
No. of women on board	1	1	1
No. of non-executive directors on board	8	8	8
Company conducts board evaluations	Yes	Yes	Yes
No. of board meetings for the year	6	5	7
Board meeting attendance pct	100	96	94
Board duration (years)	3	3	3
Director share ownership guidelines	No	No	No
Age of the youngest director	32	33	34
Age of the oldest director	80	81	82
No. of executives / company managers	6	6	e
No. of female executives	- 1	1	
Executive share ownership guidelines	No	No	No
Size of audit committee	3	3	
No. of ID on audit committee	3	3	3
Audit committee meetings	4	4	2
Audit meeting attendance %	100	100	100
Size of compensation committee	3	3	100
No. of ID on compensation committee	1	1	
No. of compensation committee meetings	2	2	2
	2 100	100	100
Compensation meeting attendance %		100 3	
Size of nomination committee	3		3
No. of nomination committee meetings Nomination meeting attendance %	2	2	3
Normalion meeting attendance %	100	100	100
Sustainability governance			

Sources: Bloomberg; FSSIA's compilation

Disclaimer for ESG scoring

ESG score	Methodolog	У			Rating						
The Dow Jones Sustainability Indices (<u>DJSI</u>) By S&P Global	process bas from the ann Only the top inclusion.	ed on the com nual S&P Glob -ranked comp	transparent, rules-basec npanies' Total Sustainabi pal Corporate Sustainabil panies within each industr	lity Scores resulting ity Assessment (CSA). ry are selected for	scoring company are disqualified. The constituents of the DJSI indices are selected from the Eligible Universe.						
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing bu Candidates i 1) no irregula float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders ome key disq ependent direc related to CG	ponsibility in Environmenta ransparency in Governar e preemptive criteria, with he board members and e s, and combined holding ualifying criteria include: ctors and free float violati , social & environmental earnings in red for > 3 yes	tice, updated annually. two crucial conditions: executives; and 2) free must be >15% of paid- 1) CG score of below on; 3) executives' impacts; 4) equity in	nature of the relevant industry and materiality.						
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by t Thailand (SE	the Thai IOD,	th in sustainable develop with support from the St Its are from the perspecti Is.	ock Exchange of	Good (80-89), and not rated f equitable treat	3 for Good (70 or scores belo nent of shareh 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (w 50. Weighting: nolders (weight 2 sure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), e rights; 2) and); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent a out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	e incorporated and sufficientl e CG compon r AGM proced and after the i sufficient informa e second assess y; and 3) openne	which shareholders' right d into business operation y disclosed. All form imp nents to be evaluated anr dures before the meeting meeting (10%). (The first a tion for voting; and 2) facilita ses 1) the ease of attending ri- ses for Q&A. The third involve ues, resolutions and voting re	s and information is ortant elements of two nually. The assessment (45%), at the meeting assesses 1) advance ting how voting rights can be neetings; 2) transparency as the meeting minutes that			four categories: (80-89), and no				
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmer policies. The (Companies d Declaration of Certification, ir managers and	nt of key contr e Certification eciding to becom Intent to kick off including risk ass employees, est	Checklist include corrupt rols, and the monitoring a is good for three years. me a CAC certified member s if an 18-month deadline to su sessment, in place of policy a tablishment of whistleblowing all stakeholders.)	and developing of start by submitting a bmit the CAC Checklist for nd control, training of	passed Check	ist will move fo se members a	ed by a committe or granting certifi re twelve highly chievements.	cation by the C	CAC Council		
<u>Morningstar</u> Sustainalytics	based on an risk is unmai regulatory filing	assessment on aged. Sources	isk rating provides an ove of how much of a compa is to be reviewed include corp ther media, NGO reports/web	ny's exposure to ESG porate publications and sites, multi-sector	more risk is un	managed, the	score is the sum higher ESG risk	is scored.			
		ompany feedbac uality & peer rev	ck, ESG controversies, issuer /iews.	feedback on draft ESG	0-10	Low 10-20	Medium 20-30	High 30-40	Severe 40+		
ESG Book	positioned to the principle helps explain over-weighti	o outperform o of financial m n future risk-a	sustainable companies the vert the long term. The materiality including inform djusted performance. Ma tith higher materiality and erly basis.	nethodology considers nation that significantly ateriality is applied by	The total ESG scores using m	score is calcul ateriality-base	ated as a weight d weights. The s dicating better p	ed sum of the score is scaled	features		
<u>MSCI</u>				anagement of financially their exposure to ESG rise					nethodology to		
	AAA	8.571-10.00	00 Leader:	leading its industry in m	anaging the most s	ignificant ESG ri	sks and opportuniti	25			
	AA	7.143-8.570	0	3 1 1 1 1		5					
	A	5.714-7.142		a mixed or unexception	al track record of m	anaging the mos	t significant ESG ri	sks and opportur	nities relative to		
	BBB BB	4.286-5.713 2.857-4.285	-	industry peers		-					
	в	1.429-2.856	6								
	ccc	0.000-1.428	Laggard:	lagging its industry base	ed on its high expos	ure and failure to	o manage significar	nt ESG risks			
Moody's ESG solutions	believes that	esses the dec t a company ir	gree to which companies	take into account ESG o to its business model and medium to long term.							
<u>Refinitiv ESG</u> rating	based on pu	blicly available	e and auditable data. The	a company's relative ES e score ranges from 0 to are 0 to 25 = poor; >25 to 50	100 on relative E	SG performar	ce and insufficie	nt degree of ti			
S&P Global				asuring a company's perf ssification. The score ran			of ESG risks, op	portunities, an	d impacts		
	500.0		Bloomberg score evalu	ating the company's agg	regated Environr			(ESG) perfor	mance. The		
Bloomberg	ESG Score		score is based on Bloo	mberg's view of ESG fina the weights are determin							

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings. Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Jitra Amornthum FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Jitra Amornthum started covering this stock from 20-Feb-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Mega Lifesciences	MEGA TB	THB 29.50	BUY	Downside risks to our DCF-based TP include 1) the delayed registration process in many countries; 2) more intensified competition; 3) failure in introducing new products; and 4) risks associated with doing business in Myanmar.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 29-Apr-2025 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months. **Neutral.** The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months. **Underweight.** The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.